Essential medicines for children

Better Medicines for Children:

Pharmaceutical Development with a Focus on Paediatric Formulations

27 February-1st March 2012, Singapore

It is generally recognized that there is to some extent, a lack of background scientific and clinical data; and information and knowledge relating to pharmaceutical development and design of paediatric medicines. An area of particular concern relates to paediatric forms of products listed in the Essential Medicines List. This includes antimalarial and tuberculosis products as well as Fixed Dose Combination (FDC) products used in the treatment of HIV/AIDS.

Therefore the WHO Prequalification of Medicines Programme (PQP) in cooperation with the Singapore Health Sciences Authority (HSA), will be holding a Training Workshop in Pharmaceutical Development with a focus on paediatric medicine.

Third Partners' Meeting on Better Medicines for Children

21-22 November 2011, Geneva, Switzerland

In order to update stakeholders on the progress of the Better Medicines for Children project and to develop synergies for future collaborations related to this work, a partners meeting on medicines for children was held in November 2011. The objectives of the meeting were: to provide feedback to stakeholders on the Better Medicines for Children Project; to identify needs for further implementation of activities in relation to improving access to and use of medicines in children and to coordinate activities.

WHO Guideline Panel on Country Pharmaceutical Pricing Policies

18-20 October 2011, Geneva, Switzerland

The Department of Essential Medicines and Pharmaceutical Policies is currently developing a WHO Guideline on Country Pharmaceutical Pricing Policies. As part of the development process, a meeting of the guideline panel is being held in October 2011. The objectives of the meeting are to appraise the available evidence on policies for managing medicine prices and to develop recommendations for medicine pricing policies in countries based on best evidence, practice and experience. The expected outcome of the meeting is a set of draft recommendations on policies and other strategies for managing pharmaceutical prices.

Informal Consultation on missing priority medicines for children

14-15 July, Geneva, Switzerland

New dosing guidelines for treating paediatric TB have been released and the benefits of prophylaxis for children with HIV have been established. However, corresponding quality, fixed-dose combination products in paediatric doses are not yet available. The objective of the meeting was to review key activities needed to encourage the development and supply of needed medicines, including rifampicin, ethambutol, isoniazid, and pyrazinamide (for TB treatment); and co-trimoxazole and isoniazid (for preventive care in HIV). This resulted in a strategy identifying the regulatory, scientific, and business activities needed to advance the manufacture of the two fixed-dose combinations.

Informal Consultation on missing priority medicines: partners working on access issues

13th July 2011, Geneva, Switzerland

"Priority medicines for mothers and children" identifies those medicines that have the highest potential for saving lives. The list of priority medicines includes a specific group of missing paediatric medicines. Multiple agencies and organizations are implementing programmes related to access to these medicines. The objective of the meeting was to review a scheme for a common approach and use it to develop an action plan. This meeting was a side meeting to the Informal consultation on missing priority medicines for children on 14-15th of July.

20 Avenue Appia
CH-1211 Geneva 27